SCHEMBL5244488

SCHEMBL5244488

O=S(=O)(Nc1cccc2cccnc12)c1cccc2nonc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.70
ALDH1A1 P00352 1/20 0.70
LMNA P02545 1/20 0.70
MAPT P10636 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
POLB P06746 2/20 0.64
GFER P55789 1/20 0.64
KMT2A Q03164 5/20 0.62
SLC40A1 Q9NP59 13/20 0.62
TDP1 Q9NUW8 4/20 0.62
MEN1 O00255 3/20 0.62
NFKBIA P25963 3/20 0.62
RELA Q04206 2/20 0.62
MDM4 O15151 1/20 0.57
OPRK1 P41145 1/20 0.57
MDM2 Q00987 1/20 0.57
G6PD P11413 1/20 0.56
AGTR1 P30556 1/20 0.56
METAP2 P50579 1/20 0.56
METAP1 P53582 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854809 0.85 SLC40A1 (0.76) GAAALDH1A1POLBKMT2ASLC40A1
SCHEMBL1507919 0.85 SLC40A1 (0.76) GAAALDH1A1POLBKMT2ASLC40A1
SCHEMBL30286472 0.81 ALDH1A1 (0.52) GAAALDH1A1LMNAMAPTL3MBTL1
SCHEMBL20354765 0.81 ALDH1A1 (0.52) GAAALDH1A1LMNAMAPTL3MBTL1
SCHEMBL6396531 0.80 ALDH1A1 (0.76) GAAALDH1A1LMNAMAPTL3MBTL1
SCHEMBL27214283 0.79 SLC40A1 (0.80) ALDH1A1LMNAMAPTKMT2ASLC40A1
SCHEMBL30925525 0.79 SLC40A1 (0.80) ALDH1A1LMNAMAPTKMT2ASLC40A1
SCHEMBL5244832 0.78 POLB (0.61) GAAALDH1A1LMNAMAPTL3MBTL1
SCHEMBL5247775 0.78 POLB (0.72) GAAALDH1A1LMNAMAPTL3MBTL1
SCHEMBL6981201 0.78 SLC40A1 (0.73) GAAKMT2ASLC40A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP GAA 488/4885ALDH1A1 2627/4885LMNA 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.